Archives arch-venture-partners

by in
Entry Author Date Location
Flagship CEO on Backing NY Biotech, Moderna, and Investing in a Boom 06/22/15 New York
After Reinvention, Pulmatrix Wraps Up Ruthigen Deal, Heads to Nasdaq 06/16/15 Boston
West Coast Biotech Roundup: PCSK9, Amgen, SeaGen, Twist, Serenus 06/11/15 Seattle
Lycera’s End Game? $104M Celgene Deal Could Lead to Buyout 06/11/15 Detroit
Denali Rises With $217M and Genentech Alumni to Fight Brain Diseases 05/14/15 San Francisco
Impinj Sells 10 Billion Chips, Unlocking Internet of Everyday Things 04/20/15 Seattle
Now Biotech-Only, Atlas Reloads With $280M Fund For New Startups 04/17/15 Boston
Join Us May 6 at the Hutch to Discuss Seattle Biotech’s Wild Ride 04/14/15 Seattle
Pop That Bubble: 5 Reasons Biotech Needs A Different Metaphor 04/14/15 National
East Coast Biotech Roundup: NY Bio Fund, Sarepta, ZappRx, & More 04/03/15 Boston
Arch, Flagship to Anchor NYCEDC’s $150M NY Biotech Fund 03/30/15 New York
East Coast Biotech Roundup: Hemophilia, Levin, Vertex, Semma & More 03/27/15 Boston
West Coast Biotech Roundup: Amgen/deCODE, Calico, Orexigen & More 03/27/15 San Diego
Flagship Ventures Raises Sails for $537M Fund, Its Largest to Date 03/26/15 Boston
Semma Secures $44M to Develop Diabetes Stem Cell Therapy 03/24/15 Boston
East Coast Biotech Roundup: Sync Project, Epizyme, Bristol & More 03/16/15 Boston
Early VC Arch Exits Ikaria with $2.3B Sale to Mallinckrodt 03/05/15 New York
Algal Biofuel Icon Sapphire Energy Moves to Diversify Product Line 02/03/15 San Diego
J.P. Morgan 2015: Notes, Thoughts, And Conversations From the Vortex 01/16/15 National
Second Exit for DeCode Investors as Spinout NextCODE Sold to WuXi 01/09/15 Boston
Juno Just Raised A Ton of Cash. Here Comes the Spending Part. 12/19/14 Seattle
More Biotechs Belly-Up These Days but Dendreon Still “One of a Kind” 12/02/14 National
West Coast Biotech Roundup: Gilead, Juno, Hutch, Fibrogen & More 11/20/14 Seattle
Juno, Less Than a Year Old, Lines up IPO to Fund Cancer Work 11/17/14 Seattle
East Coast Biotech Roundup: Sarepta, Aegerion, Syros, Aileron & More 10/31/14 Boston
Syros Raises $53M More To Push Gene-Control Drugs Into Human Trials 10/27/14 Boston
Six Takeaways from Boston’s Life Science Disruptors 10/13/14 Boston
Sold For Parts, Accelerator Grad Allozyne Reaches End of the Line 09/18/14 Seattle
Scholar Rock’s Local Approach to Immune Disease Nabs $20M 09/15/14 Boston
John Maraganore: From “Prototypical Geek” To Canny Alnylam Chief 09/07/14 Boston
Page 1 of 14 next page »